• All
  • Primary Antibodies
  • Conjugated Antibodies for IF
  • Conjugated Antibodies for FC
  • Secondary Antibodies
  • Antibody Labeling KitsNew
  • ELISA Kits
  • IHC Kits
  • Magnetic Cell Separation Kits
  • Cytokines & Growth Factors
  • Neutralizing/activating Antibodies
  • Nanobody-based Reagents
  • Accessory Products and Kits
  • Fusion Proteins
×
×
Host
0
Species Reactivity
0
Species Reactivity
0
Conjugate
0
Conjugate
0
Compatible Species
0
Conjugate
0

Anticorps Recombinant de lapin anti-SARS-CoV-2 Spike

SARS-CoV-2 Spike Recombinant Antibody for Neutralization, ELISA

Hôte / Isotype

Human / IgG1

Réactivité testée

Virus

Applications

Neutralization, ELISA

Conjugaison

Non conjugué

CloneNo.

AM001414

N° de cat : 91361-PTG

Synonymes

SARS-CoV-2, SARS-CoV-2 Spike, Spike

Galerie de données de validation

Filter:
  • Neutralization experiment of SARS-CoV-2 Spike using SARS-CoV-2 Spike Recombinant antibody (91361-PTG)

    Neutralization experiment of SARS-CoV-2 Spike using 91361-PTG

    SARS-CoV-2 Spike Antibody (clone AM001414) tested by Neutralization.Viral neutralization assays were performed with pseudotyped virus carrying a luciferase reporter gene and bearing the SARS-CoV-2 S1 spike glycoprotein. A549 lung epithelial target cells expressing the ACE2 receptor were incubated with virus and a graded dose of SARS-CoV-2 Spike Antibody (clone AM001414). Luciferase signal, indicative of cellular infection and viral gene expression, was measured. Viral neutralization by SARS-CoV-2 antibodies inhibits viral entry and, by extension, virus associated luciferase signal in manner proportional to antibody dose. Data provided by Active Motif®. .

  • ELISA experiment of SARS-CoV-2 Spike RBD protein using SARS-CoV-2 Spike Recombinant antibody (91361-PTG)

    ELISA experiment of SARS-CoV-2 Spike RBD protein using 91361-PTG

    SARS-CoV-2 Spike Antibody (clone AM001414) tested by ELISA.SARS-CoV-2 Spike RBD protein was coated onto microtiter plates at 0.5 µg/mL and then incubated with a dilution series of SARS-CoV-2 Spike Antibody (clone AM009105). Bound antibodies were detected with anti-human IgG conjugated to horseradish peroxidase (HRP) followed by incubation with HRP Substrate and then measuring the resulting absorbance at 450 nm. Data provided by Active Motif®. .

Applications testées

Résultats positifs en Neutralizationvirus pseudotypé
Résultats positifs en ELISADomaine RBD de la protéine Spike du SARS-CoV-2

Dilution recommandée

ApplicationDilution
Sample dependent. To be determined by the end user.

Remarque: Proteintech is partnering with Active Motif to bring these cutting-edge, patient derived antibodies to our customers during this important time for COVID-19 research.

Informations sur le produit

91361-PTG cible SARS-CoV-2 Spike dans les applications de Neutralization, ELISA et montre une réactivité avec des échantillons Virus

Réactivité Virus
Hôte / Isotype Human / IgG1
Clonalité Recombinant
Type Anticorps
Immunogène Virus
Nom complet SARS-CoV-2 Spike Protein
Masse moléculaire calculée 141 kDa
Numéro d’acquisition GenBankNC_045512
Symbole du gène COVID-19 S Protein
Identification du gène (NCBI) 43740568
Conjugaison Non conjugué
Forme Liquide
Méthode de purification Chromatographie par protéine A
Tampon de stockage Hepes 140 mM, pH 7,5, NaCl 70 mM, NaOAc 32 mM, azoture de sodium à 0,035 % et glycérol à 30 %.
Conditions de stockageStocker à -20°C. Stable pendant un an après l'expédition. L'aliquotage n'est pas nécessaire pour le stockage à -20oC Les 20ul contiennent 0,1% de BSA.

Informations générales

COVID-19, which is short for coronavirus disease 2019, is the official name of the respiratory disease caused by infection with the novel coronavirus SARS-CoV-2. The virus that causes COVID-19 was named SARS-CoV-2 because it is a coronavirus genetically similar to, yet distinct from, the virus that caused the severe acute respiratory syndrome (SARS) outbreak in 2003. Studying the details of how this virus replicates and causes the disease will allow scientists and physicians to more rapidly develop fast and accurate methods of detection as well as to deploy therapeutic and vaccine strategies. This antibody was derived from COVID-19 patients who have cleared the virus. Patient serum IgG was sequenced and expressed as full-length IgG1 with human immunoglobulin heavy and light chains in mammalian 293 cells.